These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 33605950)
1. Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers. Flanagan SP; Fogel R; Edkins AL; Ho LSJ; Limson J Anal Methods; 2021 Mar; 13(9):1191-1203. PubMed ID: 33605950 [TBL] [Abstract][Full Text] [Related]
2. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059 [TBL] [Abstract][Full Text] [Related]
3. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Ferreira CS; Matthews CS; Missailidis S Tumour Biol; 2006; 27(6):289-301. PubMed ID: 17033199 [TBL] [Abstract][Full Text] [Related]
4. Dual-targeting CD44 and mucin by hyaluronic acid and 5TR1 aptamer for epirubicin delivery into cancer cells: Synthesis, characterization, Jamshidi Z; Dehghan R; Nejabat M; Abnous K; Taghdisi SM; Hadizadeh F Heliyon; 2024 Jan; 10(2):e24833. PubMed ID: 38312665 [TBL] [Abstract][Full Text] [Related]
5. In vitro selection of aptamer S1 against MCF-7 human breast cancer cells. Zhang WY; Chen HL; Chen QC Bioorg Med Chem Lett; 2019 Aug; 29(16):2393-2397. PubMed ID: 31196711 [TBL] [Abstract][Full Text] [Related]
6. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo. Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594 [TBL] [Abstract][Full Text] [Related]
7. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Ferreira CS; Papamichael K; Guilbault G; Schwarzacher T; Gariepy J; Missailidis S Anal Bioanal Chem; 2008 Feb; 390(4):1039-50. PubMed ID: 17694298 [TBL] [Abstract][Full Text] [Related]
8. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo. Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619 [TBL] [Abstract][Full Text] [Related]
9. A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells. Bahreyni A; Yazdian-Robati R; Hashemitabar S; Ramezani M; Ramezani P; Abnous K; Taghdisi SM Int J Pharm; 2017 Jun; 526(1-2):391-399. PubMed ID: 28495579 [TBL] [Abstract][Full Text] [Related]
10. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795 [TBL] [Abstract][Full Text] [Related]
11. Targeted imaging of breast cancer cells using two different kinds of aptamers -functionalized nanoparticles. Mohammadinejad A; Taghdisi SM; Es'haghi Z; Abnous K; Mohajeri SA Eur J Pharm Sci; 2019 Jun; 134():60-68. PubMed ID: 30970280 [TBL] [Abstract][Full Text] [Related]
12. Gold nanoparticle-streptavidin conjugates for rapid and efficient screening of aptamer function in lateral flow sensors using novel CD4-binding aptamers identified through Crossover-SELEX. Fellows T; Ho L; Flanagan S; Fogel R; Ojo D; Limson J Analyst; 2020 Aug; 145(15):5180-5193. PubMed ID: 32567629 [TBL] [Abstract][Full Text] [Related]
13. Importance of rigorous in vitro evaluation of prospective cell binding aptamers. Avci-Adali M; Mludek K; Perle N; Stoll H; Schlensak C; Wendel HP Nucleic Acid Ther; 2014 Aug; 24(4):250-7. PubMed ID: 25054517 [TBL] [Abstract][Full Text] [Related]
14. The application of aptamer 5TR1 in triple negative breast cancer target therapy. Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278 [TBL] [Abstract][Full Text] [Related]
15. An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Liu M; Wang Z; Tan T; Chen Z; Mou X; Yu X; Deng Y; Lu G; He N Theranostics; 2018; 8(20):5772-5783. PubMed ID: 30555580 [TBL] [Abstract][Full Text] [Related]
16. Aptamer-tagged silver nanoclusters for cell image and Mucin1 detection in vitro. Zhou L; Wang W; Chen Y; Fan J; Tong C; Liu B Talanta; 2019 Dec; 205():120075. PubMed ID: 31450473 [TBL] [Abstract][Full Text] [Related]
17. Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting. Li Z; Hu Y; An Y; Duan J; Li X; Yang XD Molecules; 2019 Jan; 24(3):. PubMed ID: 30699986 [TBL] [Abstract][Full Text] [Related]
18. Theoretical modeling of masking DNA application in aptamer-facilitated biomarker discovery. Cherney LT; Obrecht NM; Krylov SN Anal Chem; 2013 Apr; 85(8):4157-64. PubMed ID: 23480390 [TBL] [Abstract][Full Text] [Related]